Innovitech

Innovitech’s strategy covers seed, startup, and growth stages, indicating a mandate that can support portfolio companies from early formation through later-stage funding rounds. The firm does not specify check-size ranges or reserve allocation policies for follow-on investments. Without confirmed portfolio companies, the degree to which it leans toward seed versus growth in practice is not publicly verifiable.

Innovitech does not publicly disclose its investment committee structure, managing partners, or senior investment professionals. This absence of named leadership is uncommon among Canadian venture firms with an active web presence. No public filings or third-party profiles identify the individuals responsible for sourcing, diligence, or portfolio management.

No corporate parent, endowment, government agency, or university affiliation is publicly disclosed for Innovitech. The firm appears to operate as an independent asset manager rather than a strategic corporate venture arm. This independence distinguishes it from Montreal-based vehicles tied to pension funds like CDPQ or university-linked programs.

The firm describes its focus broadly as technology investing, without specifying vertical concentrations such as artificial intelligence, enterprise software, or healthtech. Montreal’s venture market has notable strengths in AI and aerospace, but no evidence ties Innovitech to these clusters. Sectors explicitly avoided are also not disclosed.

No fundraises, limited partner disclosures, or regulatory filings such as Form ADV are publicly available for Innovitech. The firm’s capital base — whether institutional, high-net-worth, or principal capital — is not stated. This opacity limits allocator assessment of the firm’s backing and governance structure.